Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK 2,010.00
+23.50 (1.18%)
Dec 17, 2025, 10:50 AM CET
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
9.13M DKK
Profits / Employee
3.76M DKK
Market Cap
122.37B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,682 | 478 | 21.69% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Dec 31, 2020 | 781 | 233 | 42.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 77,349 |
| Demant | 22,639 |
| Coloplast | 16,744 |
| GN Store Nord | 7,347 |
| H. Lundbeck | 5,707 |
| Ambu A/S | 5,384 |
| Embla Medical | 4,061 |
| ALK-Abelló | 2,753 |
Genmab News
- 5 days ago - Genmab Meets Conditions For $97/shr Merus Tender Offer - Nasdaq
- 5 days ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire
- 5 days ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - GlobeNewsWire
- 5 days ago - Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions - Slideshow - Seeking Alpha
- 5 days ago - Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript - Seeking Alpha
- 6 days ago - Genmab to Hold 2025 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 8 days ago - Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial - GuruFocus
- 8 days ago - Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - Business Wire